Pure Global
NCT06259721

Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Efficacy and Safety of Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma: A Single-arm, Open-label, Multi-center Phase II Clinical Trial
Jiangxi Provincial Cancer Hospital·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Nasopharyngeal Carcinoma
Drug/Device/Intervention
Anti-PD1 antibody, nimotuzumab and capecitabine
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Jiangxi Provincial Cancer Hospital
Location
Nanchang, China
Timeline & enrollment
Phase
Phase 2
Start date
Feb 10, 2024
End date
Aug 09, 2026
Enrollment
22 participants
Primary outcome

Objective response rate

Summary

The purpose of this study is to explore the efficacy and safety of a combination regimen of
 Anti-PD1 monoclonal antibody, nimotuzumab, and capecitabin in treating recurrent or
 metastatic nasopharyngeal carcinoma patients who have failed first-line platinum-based
 chemotherapy.

ICD-10 classifications
Malignant neoplasm of nasopharynxMalignant neoplasm: Nasopharynx, unspecifiedMalignant neoplasm: Overlapping lesion of nasopharynxBenign neoplasm: NasopharynxMalignant neoplasm: Posterior wall of nasopharynx
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06259721
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06259721 through Pure Global AI's free database. This Phase 2 trial is sponsored by Jiangxi Provincial Cancer Hospital and is currently Recruiting. The study focuses on Nasopharyngeal Carcinoma. Target enrollment is 22 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.